Promising Phase 2 Vaccine Results

Clover Announces Positive Phase 2 Clinical Data for Respiratory Vaccine Candidates in Older Adults

Clover Biopharmaceuticals, Ltd. has announced positive Phase 2 clinical data for RSV+hMPV±PIV3 combination vaccines in Australia, demonstrating potential best-in-class profile and potential ability to re-vaccinate individuals previously receiving approved RSV vaccines to restore and broaden protection. The company also highlighted a strong safety and tolerability profile and successful 2,000L commercial-scale production. The ongoing Phase 2 trial for Clover's combination vaccine candidates is a randomized, observer-blinded, multi-center study with 420 older adults (60-85 years) in Australia. Antibody titers at 28 days post-vaccination were generally in-line with or trended higher than the prior Phase 1 trial. Approximately 62% lower rate of respiratory tract infection was observed in the vaccine groups (SCB-1022) and SCB-1133.